Transdermal Drug Delivery System Market Outlook
According to the USD Analytics published latest research report, the global “Transdermal Drug Delivery System Market” is expected to grow at a tremendous CAGR of 4.6% during the forecast period 2023-2030.
A transdermal drug delivery system (TDDS) delivers drugs via the skin at a predetermined and regulated rate. These techniques treat various medical conditions involving the heart and nervous system. Skin patches can be used to deliver medications including nicotine (for stopping smoking), scopolamine (for travel sickness or motion sickness), lidocaine (for shingles pain), and nitro-glycerin (for angina).
These devices have many advantages, including a longer therapeutic impact, fewer side effects, higher bioavailability, improved patient compliance, and easier drug treatment termination. Drugs enter the body via three primary pathways: appendageal, transcellular, and intercellular.
Market Drivers:
Increase in Self-Administration of Long-Term Drugs
Transdermal drug delivery devices have improved drug diffusion capabilities compared to more conventional medication administration routes such as intravenous, oral, and pulmonary. The rising demand for pain-free medication administration among patients and professionals is a major driver in the widespread usage of TDDS. The greater accessibility for self-administration of drugs for conditions that need long-term treatment, such as diabetic patients, is boosting the TDDS application.
Presence of Numerous Transdermal Products in Clinical Trial Phases
There are presently multiple ongoing clinical studies for FDA-approved transdermal products. These studies range from Phase I through IV, and the majority use transdermal devices that have already acquired FDA clearance for medications such as fentanyl, nicotine, and hormone therapies. This research covers a broad spectrum of disease situations, with many exploring novels uses for existing transdermal products or other pharmacological combinations.
Browse Full Report @ https://www.usdanalytics.com/industry-reports/transdermal-drug-delivery-system-market
Market Restraints:
Skin Layers Posing as a Barrier in Achieving Maximum Efficiency
Most transdermal drugs do not achieve their full potential because of the built-in skin barrier. The skin’s job, as the body’s outermost organ with numerous layers, is to protect it from the outside world by sheltering it from toxins, heat, and chemicals. The epidermis, which functions as a barrier, and the dermis, which contains blood vessels and creates skin cells, are components of such skin that block transdermal distribution. The problem of medication permeability through the skin would hamper the growth of the transdermal drug delivery systems industry.
Covid-19 Impact Analysis:
The COVID-19 epidemic harmed the transdermal medication delivery system business. The strict lockdown measures enacted by several countries throughout the globe produced a big gap in product demand and supply, resulting in a drop in transdermal medicine delivery system sales. Furthermore, lower patient hospital visits due to delays and cancellations of elective medical operations hampered product consumption, influencing trade dynamics during the crisis.
Recent Industry Developments:
- In March 2022: The United States Food and Drug Administration approved the first generic Symbicort (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol in March 2022 for the treatment of two common pulmonary health conditions, asthma in patients six years of age and older and chronic obstructive pulmonary disease (COPD), such as chronic bronchitis and emphysema.
- In June 2021: Shilpa Medicare Ltd., under the trade name Molshil, developed an oral thin film formulation, a pediatric dosage of paracetamol oral thin film, in June 2021. Shilpa was granted permission for Molshil oral thin films after meeting bioequivalence conditions. Shilpa’s paracetamol oral thin films are patent protected and the world’s first of their type.
- In December 2020: Twirla (levonorgestrel and Ethinyl estradiol) transdermal drug delivery devices, a novel non-daily, non-invasive contraceptive patch, to be commercially introduced in the United States by Agile Therapeutics, Inc. in December 2020.
Transdermal Drug Delivery System Market Segmentation Analysis:
By Technology
- Electroporation
- Radio Frequency
- Iontophoresis
- Microporation
- Thermal
- Mechanical arrays
- Ultrasound
- Others
By Application
- CNS
- Pain Management
- Cardiovascular
- Hormone
- Immunological
- Metabolic
- Gastrointestinal
- Infection
- Cancer
- Others
The iontophoresis segment dominated the market in 2022 and is projected to be the faster-growing segment during the forecast period. It encourages ion movement across the membrane in response to a tiny externally applied potential difference, which has been shown to improve skin penetration and increase the release rate of numerous transdermal drug delivery systems with poor absorption/permeation profiles. However, due to an increasing number of product launches by prominent industry players and the innumerable microneedle or mechanical array transdermal drug delivery systems products in the late stages of clinical trials, microporation is the fastest-growing category over the forecast period.
Download Sample Report @ https://www.usdanalytics.com/sample-request/3181
Geographical Analysis:
The global transdermal drugs delivery system market is segmented into North America, Europe, South America, Asia Pacific, and Middle East & Africa.
North America Transdermal Drugs Delivery System Market
North American region had the most revenue share in the transdermal drug delivery systems market in 2022. Patent expirations, which result in new entrants into the market, are a major driver of development in this area. Furthermore, significant investments made by both established and new market entrants, reformulation of active drug compounds, repositioning of previously unsuccessful drugs, and other factors all play an important role in the sizable share this region has managed to capture.
Competitive Landscape:
The key players contributing to the global transdermal drugs delivery system market growth include • Novartis AG, Johnson and Johnson Inc., Viatris Inc., Boehringer Ingelheim GmbH. Biogel Technology, Inc., 3M Company, Noven Pharmaceuticals, Inc., Nutriband Inc., Transdermal Corporation, Echo Therapeutics, Inc., and other major companies.
Related Reports:
Ophthalmic Drug Delivery Systems Market Size, Share, Trends, Growth Outlook and Opportunities to 2030-by Technology (Eye drops, Contact lenses, Punctal plugs, Episcleral Implants, Intravitreal Implants, Injectable Particulate Systems, Iontophoresis, Micro-Electromechanical, Nano careers, Nano microparticles, Microneedles, Hydrogels, Others), by Route of Administration (Intraocular, Intravitreal, Intracameral), by Production (Electrospinning, 3D printing, Extrusion, Formulation, Micro patterning, Compression molding, Others), and Companies Report
Pulmonary Drug Delivery Systems Market Size, Share, Trends, Growth Outlook and Opportunities to 2030-by Type (Metered Dose Inhalers, Dry Powder Inhalers, Nebulizers, Accessories), by Application (Asthma, Cystic Fibrosis, COPD, Allergic Rhinitis, Others), by End-Use (Hospital and Clinics, Homecare), and Companies Report
Electronic Drug Delivery Systems Market Size, Share, Trends, Growth Outlook and Opportunities to 2030-by Type (Wearable infusion pumps, Auto injectors, Injection pens, Inhalers), by Application (Diabetes, Cardiovascular diseases, Respiratory disorders, Multiple sclerosis, Others), by Sales channel (Hospital pharmacies, Retail pharmacies, Online pharmacies), and Companies Report
Media Contact
Company Name: USD Analytics
Contact Person: Harry James
Email: Send Email
Country: India
Website: https://www.usdanalytics.com/industry-reports/transdermal-drug-delivery-system-market